Search Result

Results for "

Neuropathic diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adenosine Receptor (2) Adrenergic Receptor (1) Apoptosis (4) Cannabinoid Receptor (1) CCR (1) Cholinesterase (ChE) (2) DNA/RNA Synthesis (2) Endogenous Metabolite (2) GPR55 (1) Histamine Receptor (1) iGluR (4) Interleukin Related (2) Isotope-Labeled Compounds (1) Keap1-Nrf2 (1) Lipoxygenase (2) mAChR (1) MAGL (1) Necroptosis (1) Opioid Receptor (2) PARP (1) Phospholipase (1) Serotonin Transporter (1) Sodium Channel (3) TNF Receptor (2) Trk Receptor (1) TRP Channel (1) α-synuclein (2)
By Research Areas:	Cancer (10) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (6) Metabolic Disease (2) Neurological Disease (18)

By Targets:

5-HT Receptor (1)

Adenosine Receptor (2)

Adrenergic Receptor (1)

Apoptosis (4)

Cannabinoid Receptor (1)

CCR (1)

Cholinesterase (ChE) (2)

DNA/RNA Synthesis (2)

Endogenous Metabolite (2)

GPR55 (1)

Histamine Receptor (1)

iGluR (4)

Interleukin Related (2)

Isotope-Labeled Compounds (1)

Keap1-Nrf2 (1)

Lipoxygenase (2)

mAChR (1)

MAGL (1)

Necroptosis (1)

Opioid Receptor (2)

PARP (1)

Phospholipase (1)

Serotonin Transporter (1)

Sodium Channel (3)

TNF Receptor (2)

Trk Receptor (1)

TRP Channel (1)

α-synuclein (2)

By Research Areas:

Cancer (10)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (6)

Metabolic Disease (2)

Neurological Disease (18)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145584

Nesuparib JPI-547/OCN-201	PARP	Cardiovascular Disease Neurological Disease
Nesuparib is a potent inhibitor of PARP. Nesuparib is useful for the research of neuropathic pain, neurodegenerative disease, and cardiovascular disease (extracted from patent WO2016200101A2) .

HY-156684

GDC-6599	TRP Channel	Neurological Disease
GDC-6599 is an orally active TRPA1 inhibitor, with IC₅₀ values of 5.3 nM in humans, 6.6 nM in rats, 9.3 nM in dogs, 7.2 nM in monkeys, and 15 nM in guinea pigs. GDC-6599 can be used in the research of neuropathic pain and respiratory diseases such as asthma and chronic cough .

HY-125111

PSB-SB-487	GPR55 Cannabinoid Receptor	Neurological Disease Metabolic Disease Cancer
PSB-SB-487 is a potent GPR55 antagonist and CB₂ agonist with an IC₅₀ value of 0.113 µM for GPR55, and a K_i value of 0.292 µM for human CB₂. PSB-SB-487 can be used for researching diabetes, Parkinson’s disease, neuropathic pain, and cancer .

HY-Y0790

Cuminaldehyde p-Isopropylbenzaldehyde	Endogenous Metabolite Apoptosis DNA/RNA Synthesis α-synuclein Lipoxygenase Opioid Receptor Interleukin Related TNF Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC₅₀= 0.00085 mg/mL), α-glucosidase (IC₅₀=0.5 mg/mL) and lipoxygenase (IC₅₀=1370 μM). Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .

HY-158338

ABHD antagonist 1	MAGL	Others Neurological Disease Inflammation/Immunology Cancer
ABHD antagonist 1 possesses ABHD6 (α/β-Hydrolase domain containing 6) inhibitory activity, involving the regulation of biochemical pathways involved in ABHD6, thereby affecting cell function and inflammatory response. ABHD antagonist 1 can be used in pain, neuropathic diseases, inflammatory diseases. Autoimmune diseases, metabolic diseases, and cancer research .

HY-155183

A3AR agonist 1	Adenosine Receptor	Inflammation/Immunology Cancer
A3AR agonist 1 (Compound 12) is an A3AR agonist (K_i: 25.8 nM). A3AR agonist 1 stimulates β-arrestin2 recruitment, with an EC₅₀ value of 5.17 nM. A3AR agonist 1 can be used for research of inflammatory diseases, ischemia, cancer, neuropathic pain, liver diseases, etc .

HY-136459

NMDA receptor antagonist 2	iGluR	Neurological Disease
NMDA receptor antagonist 2 is a potent and orally active NR2B subtype-selective NMDA antagonist with an IC₅₀ and a K_i of 1.0 nM and 0.88 nM, respectively. NMDA receptor antagonist 2 is used for the study of neuropathic pain and Parkinson’s disease .

HY-156596

Aneratrigine	Sodium Channel	Neurological Disease
Aneratrigine is a sodium channel protein type 9 subunit alpha blocker. Aneratrigine can be used for neuropathic pain diseases research .

HY-156596A

Aneratrigine hydrochloride	Sodium Channel	Neurological Disease
Aneratrigine (hydrochloride) is a sodium channel protein type 9 subunit alpha blocker. Aneratrigine (hydrochloride) can be used for neuropathic pain diseases research .

HY-143583

ATX inhibitor 10	Others	Neurological Disease Cancer
ATX inhibitor 10 is a potent inhibitor of ATX. ATX inhibitor 10 is s nitrogen-containing heterocyclic compound. ATX plays a role in causing pathological conditions including fibrosis, arthritis, neurodegeneration, neuropathic pain, and cancer. ATX inhibitor 10 has the potential for the research of ATX related diseases (extracted from patent WO2021115375A1, compound 35) .

HY-127110

AK106-001616	Phospholipase	Others Neurological Disease Inflammation/Immunology
AK106-001616 is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2) (IC₅₀=3.8 nmol/L). AK106-001616 is able to reduce the production of prostaglandins (PG) E2 and leukotrienes (LT) B4 by stimulated cells. AK106-001616 can be used in the study of inflammatory diseases, neuropathic pain and pulmonary fibrosis .

HY-144200

CCR8 antagonist 2	CCR	Neurological Disease Cancer
CCR8 antagonist 2 is a potent antagonist of CCR8. CCR8 (C-C Motif Chemokine Receptor 8) is predominantly expressed on Treg cells and Th2 cells, but not on Th1 cells. CCR8 antagonist 2 inhibits CCR8 activity, which may be used in the research of diseases mediated by CCR8, such as cancer, and/or neuropathic pain (extracted from patent WO2022000443A1, compound 220) .

HY-155184

A3AR agonist 2	Adenosine Receptor	Neurological Disease Inflammation/Immunology Cancer
A3AR agonist 2 (Compound 19) a selective A3AR agonist (K_i: 22.1 nM). A3AR agonist 2 stimulates β-arrestin2 recruitment, with EC₅₀ value of 4.36 nM. A3AR agonist 2 can be used for research of inflammatory diseases, ischemia, cancer, neuropathic pain, liver diseases, and other chronic conditions . A3AR agonist 2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-167862

UCM-05194	Others	Neurological Disease
UCM-05194 is a selective LPA1 receptor agonist with activity to improve neuropathic pain. UCM-05194 is a LPA1 agonist that exhibits potent and selective properties in its pharmacologically similar properties. UCM-05194 triggers LPA1-mediated cellular effects and leads to internalization of the receptor, resulting in functional inactivation in primary sensory neurons. UCM-05194 effectively reduces pain perception in in vivo models. UCM-05194 can be used to conduct research on progressive systemic diseases .

HY-17387

(-)-Huperzine A 4 Publications Verification Huperzine A	Cholinesterase (ChE) Apoptosis iGluR	Neurological Disease
(-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC₅₀ of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease .

HY-17387S1

(-)-Huperzine A-d4 hydrochloride Huperzine A-d₄	iGluR Cholinesterase (ChE) Apoptosis Isotope-Labeled Compounds	Neurological Disease
(-)-Huperzine A-d₄ hydrochloride is deuterated labeled (-)-Huperzine A (HY-17387). (-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC₅₀ of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease .

HY-B0527A

Amitriptyline hydrochloride 4 Publications Verification	Serotonin Transporter 5-HT Receptor Histamine Receptor mAChR Adrenergic Receptor Sodium Channel Trk Receptor	Neurological Disease Cancer
Amitriptyline hydrochloride is an inhibitor of serotonin reuptake transporter (SERT) and noradrenaline reuptake transporter (NET), with K_is of 3.45 nM and 13.3 nM for human SERT and NET, respectively. Amitriptyline hydrochloride also weakly binds to dopamine reuptake transporter (DAT) with a K_i of 2.58 μM. Amitriptyline hydrochloride also inhibits adrenergic, muscarinic, histamine and 5-HT receptors. Amitriptyline hydrochloride is a TrkA and TrkB receptors agonist with potent neurotrophic activity. Amitriptyline hydrochloride has antidepressant activity .

HY-14909

Bardoxolone Maximum Cited Publications 15 Publications Verification CDDO; RTA 401	Keap1-Nrf2 Necroptosis	Metabolic Disease Cancer
Bardoxolone (RTA 401; CDDO) is a novel nuclear regulatory factor (NRf-2) activator. Bardoxolone is a potent necroptosis inhibitor that inhibits Z-VAD-FMK-induced necroptosis. Bardoxolone methyl enhances the antioxidant system, modulates inflammatory cytokines and inhibits apoptosis in rat kidney, demonstrating inhibition on APAP-induced acute kidney injury (AKI) and analgesic effect. Additionally, Bardoxolone methyl decreases Paclitaxel (PAC) (HY-B0015)-induced mitochondrial damage in neuronal cells. Bardoxolone methyl is promising for the research of chemotherapy-induced neuropathic pain and chronic kidney disease .

HY-Y0790R

Cuminaldehyde (Standard)	Endogenous Metabolite Apoptosis DNA/RNA Synthesis α-synuclein Lipoxygenase Opioid Receptor Interleukin Related TNF Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
Cuminaldehyde (Standard) is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC₅₀= 0.00085 mg/mL) and α-glucosidase (IC₅₀=0.5 mg/mL). Cuminaldehyde can modulate α-synuclein fibrils. Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .

HY-147352

NMDA receptor potentiator-1	iGluR	Neurological Disease
NMDA receptor potentiator-1 (Compound 1368) is a subunit selective NMDA receptor potentiator with IC₅₀s of 4 μM and 5 μM against NR2C and NR2D expression, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-Y0790

Cuminaldehyde p-Isopropylbenzaldehyde	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Rudbeckia laciniata L. Source classification Umbelliferae Plants Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite Apoptosis DNA/RNA Synthesis α-synuclein Lipoxygenase Opioid Receptor Interleukin Related TNF Receptor
Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC₅₀= 0.00085 mg/mL), α-glucosidase (IC₅₀=0.5 mg/mL) and lipoxygenase (IC₅₀=1370 μM). Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .

HY-17387

(-)-Huperzine A 4 Publications Verification Huperzine A	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Anti-aging Terpenoids Huperziaceae Sesquiterpenes Pyridine Alkaloids Huperzia serrata Plants Disease Research Fields	Cholinesterase (ChE) Apoptosis iGluR
(-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC₅₀ of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease .

HY-Y0790R

Cuminaldehyde (Standard)	Structural Classification Ketones, Aldehydes, Acids Rudbeckia laciniata L. Source classification Umbelliferae Plants Endogenous metabolite	Endogenous Metabolite Apoptosis DNA/RNA Synthesis α-synuclein Lipoxygenase Opioid Receptor Interleukin Related TNF Receptor
Cuminaldehyde (Standard) is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC₅₀= 0.00085 mg/mL) and α-glucosidase (IC₅₀=0.5 mg/mL). Cuminaldehyde can modulate α-synuclein fibrils. Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .

Cat. No.	Product Name	Chemical Structure

HY-17387S1

(-)-Huperzine A-d4 hydrochloride
(-)-Huperzine A-d₄ hydrochloride is deuterated labeled (-)-Huperzine A (HY-17387). (-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC₅₀ of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease .

(-)-Huperzine A-d4 hydrochloride

(-)-Huperzine A-d₄ hydrochloride is deuterated labeled (-)-Huperzine A (HY-17387). (-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC₅₀ of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks